1,148
Views
0
CrossRef citations to date
0
Altmetric
Cardiovascular

Assessment of clinical and economic impact of rivaroxaban plus aspirin vs. aspirin alone as a secondary prophylaxis in patients with chronic and symptomatic peripheral arterial disease in the United States

, , , &
Pages 10-15 | Received 15 Sep 2023, Accepted 29 Nov 2023, Published online: 09 Dec 2023

Reprints and Permissions

Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.

To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.

For more information please visit our Permissions help page.